These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 10653303

  • 21. Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study.
    Zappia M, Annesi G, Nicoletti G, Arabia G, Annesi F, Messina D, Pugliese P, Spadafora P, Tarantino P, Carrideo S, Civitelli D, De Marco EV, Cirò-Candiano IC, Gambardella A, Quattrone A.
    Arch Neurol; 2005 Apr; 62(4):601-5. PubMed ID: 15824260
    [Abstract] [Full Text] [Related]

  • 22. The motor inhibition system in Parkinson's disease with levodopa-induced dyskinesias.
    Cerasa A, Donzuso G, Morelli M, Mangone G, Salsone M, Passamonti L, Augimeri A, Arabia G, Quattrone A.
    Mov Disord; 2015 Dec; 30(14):1912-20. PubMed ID: 26275050
    [Abstract] [Full Text] [Related]

  • 23. Development of dyskinesias in a 5-year trial of ropinirole and L-dopa.
    Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE, Abdalla M, 056 Study Group.
    Mov Disord; 2006 Nov; 21(11):1844-50. PubMed ID: 16958094
    [Abstract] [Full Text] [Related]

  • 24. [Incidence and determinants of levodopa-induced dyskinesia in a retrospective cohort of Mexican patients with Parkinson's disease].
    Cervantes-Arriaga A, Rodríguez-Violante M, Salmerón-Mercado M, Calleja-Castillo J, Corona T, Yescas P, Alonso-Vilatela E.
    Rev Invest Clin; 2012 Nov; 64(3):220-6. PubMed ID: 23045943
    [Abstract] [Full Text] [Related]

  • 25. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990.
    Van Gerpen JA, Kumar N, Bower JH, Weigand S, Ahlskog JE.
    Arch Neurol; 2006 Feb; 63(2):205-9. PubMed ID: 16476808
    [Abstract] [Full Text] [Related]

  • 26. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease.
    Warren Olanow C, Kieburtz K, Rascol O, Poewe W, Schapira AH, Emre M, Nissinen H, Leinonen M, Stocchi F, Stalevo Reduction in Dyskinesia Evaluation in Parkinson's Disease (STRIDE-PD) Investigators.
    Mov Disord; 2013 Jul; 28(8):1064-71. PubMed ID: 23630119
    [Abstract] [Full Text] [Related]

  • 27. Levodopa-induced dyskinesia: clinical features, incidence, and risk factors.
    Tran TN, Vo TNN, Frei K, Truong DD.
    J Neural Transm (Vienna); 2018 Aug; 125(8):1109-1117. PubMed ID: 29971495
    [Abstract] [Full Text] [Related]

  • 28. Risk factors on the occurrence of response fluctuations and dyskinesias in Parkinson's disease.
    Wu RM, Chiu HC, Wang M, Chen RC.
    J Neural Transm Park Dis Dement Sect; 1993 Aug; 5(2):127-33. PubMed ID: 8333908
    [Abstract] [Full Text] [Related]

  • 29. Do parkinsonian symptoms and levodopa-induced dyskinesias start in the foot?
    Vidailhet M, Bonnet AM, Marconi R, Gouider-Khouja N, Agid Y.
    Neurology; 1994 Sep; 44(9):1613-6. PubMed ID: 7936284
    [Abstract] [Full Text] [Related]

  • 30. [Levodopa-induced psychosis in patients with idiopathic Parkinson disease].
    García-Escrig M, Bermejo Pareja F, Fernández Ponsatí JT.
    Med Clin (Barc); 1999 Feb 27; 112(7):245-50. PubMed ID: 10220750
    [Abstract] [Full Text] [Related]

  • 31. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.
    Colzi A, Turner K, Lees AJ.
    J Neurol Neurosurg Psychiatry; 1998 May 27; 64(5):573-6. PubMed ID: 9598668
    [Abstract] [Full Text] [Related]

  • 32. "Early" initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease.
    Cedarbaum JM, Gandy SE, McDowell FH.
    Neurology; 1991 May 27; 41(5):622-9. PubMed ID: 2027475
    [Abstract] [Full Text] [Related]

  • 33. [Motor complications in patients with Parkinson disease treated with levodopa].
    Luquin MR, Obeso JA, Martínez-Lage JM.
    Neurologia; 1989 May 27; 4(1):4-11. PubMed ID: 2631806
    [Abstract] [Full Text] [Related]

  • 34. Sickness due to levodopa-induced neck dyskinesias in Parkinson's disease.
    Steiger MJ, Quinn NP, Marsden CD.
    Mov Disord; 1991 May 27; 6(1):91-2. PubMed ID: 2005934
    [No Abstract] [Full Text] [Related]

  • 35. Dopaminergic treatment is associated with decreased body weight in patients with Parkinson's disease and dyskinesias.
    Bachmann CG, Zapf A, Brunner E, Trenkwalder C.
    Eur J Neurol; 2009 Aug 27; 16(8):895-901. PubMed ID: 19374662
    [Abstract] [Full Text] [Related]

  • 36. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias.
    de la Fuente-Fernández R, Sossi V, Huang Z, Furtado S, Lu JQ, Calne DB, Ruth TJ, Stoessl AJ.
    Brain; 2004 Dec 27; 127(Pt 12):2747-54. PubMed ID: 15329355
    [Abstract] [Full Text] [Related]

  • 37. Pathogenesis of dyskinesias in Parkinson's disease.
    Mouradian MM, Heuser IJ, Baronti F, Fabbrini G, Juncos JL, Chase TN.
    Ann Neurol; 1989 May 27; 25(5):523-6. PubMed ID: 2774496
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia.
    Horstink MW, Zijlmans JC, Pasman JW, Berger HJ, van't Hof MA.
    J Neurol Neurosurg Psychiatry; 1990 Mar 27; 53(3):224-6. PubMed ID: 2324754
    [Abstract] [Full Text] [Related]

  • 40. Opioid K receptor variant is associated with a delayed onset of dyskinesias in Parkinson's disease.
    Cilia R, Asselta R, Cereda E, Benfante R, Barbella G, Vallauri D, Marabini L, Fornasari D, Goldwurm S, Pezzoli G.
    J Neurol Neurosurg Psychiatry; 2018 Mar 27; 89(3):323-324. PubMed ID: 28724719
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.